アデノ関連ウイルスがアルギナットと結合し,その制御された放出の特徴
John J Amante1, James R Mandeville1, Hannah Hargrove2
1Department of Biomedical Engineering, University of Massachusetts Amherst, Life Science Laboratories 240 Thatcher Road Amherst MA 01002 USA ckearney@umass.edu.
Nanoscale advances
|February 16, 2026
まとめ
アデノ関連ウイルス (AAV) はアルジナート水素ゲルに結合し,遺伝子治療の投与に影響を与えます. この相互作用はAAVの血清型によって変化し,局所的な治療のための制御された放出に影響を与えます.
科学分野:
- バイオテクノロジー バイオテクノロジー
- 遺伝子療法の遺伝子治療法
- 材料科学 材料科学とは
背景:
- 遺伝子療法は,アデノ関連ウイルス (AAV) のようなウイルスベクターを利用して治療します.
- 現在の投与方法 (注射) は,局所化および非標的効果の制限があります.
- ウイルスのベクトルの制御された局所的配送のための水素ガスは,探索されています.
研究 の 目的:
- アルジナートヒドロゲルとアデノ関連ウイルス (AAV) の相互作用を調査する.
- AAVとアルジナートとの間の結合力と周波数を特徴付けるために.
- AAV-アルギナート相互作用が血清型に依存し,持続的な放出に影響を与えるかどうかを判断する.
主な方法:
- AAV-アルギナート相互作用を定量化するために原子力顕微鏡 (AFM) を利用しました.
- 異なるAAV血清型における結合 afinity と frequency をテストした.
- AAVの血清型-アルギナート結合が,ヒドロゲルからの持続放出キネティクスに与える影響を分析した.
主要な成果:
- AAVとアルジナートとの間の直接的な結合相互作用を発見した.
- AFM経由でアルジナートに結合するAAVの力と頻度を定量化しました.
- AAV-アルギナート相互作用の強度は血清型に依存することを実証した.
- 血清型特異的結合がアルギナート水素ゲルからAAVの持続的な放出率に影響することを示した.
結論:
- アルジナートヒドロゲルは,AAVと特定の結合相互作用を示します.
- AAV-アルギナート相互作用は血清型に依存し,結合特性に影響します.
- この血清型特異的な相互作用は,アルジナートからAAVの持続的な放出プロファイルに直接影響を及ぼし,標的型遺伝子治療の提供に関する洞察を提供します.
関連する概念動画
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...